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Abstract 
Several lines of evidence suggest that increased generation of auto-oxidized dopamine 
(DA) o-quinone is associated with the neurotoxicity of methamphetamine (MAP) in the brain, 
and that, as a cellular defenses against DA-derived quinines, glutathione S-transferase (GST) 
detoxifies auto-oxidized DA o-quinone in the brain. GSTM1 of the mu-class of GSTs catalyzes 
reaction between glutathione and catecholamine o-quinones under physiological conditions. 
This study was undertaken to investigate the role of the GSTM1 gene deletion polymorphism in 
the neuropathology of MAP abuse. One hundred and fifty-seven MAP abusers and 200 healthy 
comparison subjects were tested for a genetic polymorphism of GSTM1. The difference in the 
frequency of deletion (D)/ non-deletion (N) alleles between the female abusers and female 
controls was close to statistical significance (p=0.071), although thee was no statistical 
difference (p=0.651) between male abusers and male controls. Furthermore, the number of 
female abusers with deletion alleles was significantly (p=0.007, odds ratio: 2.77, 95% CI 
1.30-5.89) higher than that of male abusers with deletion alleles. These findings suggest that 
GSTM1 gene deletion may contribute to a vulnerability to MAP abuse in female subjects, but 
not in male subjects.  
Key words: methamphetamine; drug abuse; Glutathione S-transferase; gender difference. 
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Introduction 
Abuse of methamphetamine (MAP) is a growing problem worldwide. Some lines of 
evidence have suggested strong genetic contributions to drug abuse vulnerability (Uhl et al., 
2002). The application of brain imaging techniques to the study of drug abuse have 
demonstrated that the density of dopamine (DA) transporters is significantly reduced in the 
caudate/putamen of MAP abusers (Volkow et al., 2001; Sekine et al., 2001), suggesting that 
long-term use of MAP causes damage to dopaminergic neurons in the human brain. 
Furthermore, it has been shown that MAP-induced neurotoxicity in the brain has been shown to 
require striatum DA and to involve mechanisms associated with oxidative stress (Cadet and 
Brannock, 1998). It is also known that DA is auto-oxidized and the corresponding DA 
o-quinone (aminochrome) is subsequently generated; moreover, aminochrome and its 
subsequent product, DA o-semiquinone, elicit redox cycling which leads to the generation of 
reactive oxygen species, which in turn degenerate dopaminergic neurons (Graham et al., 1978; 
Smythies et al., 1998). DA oxidation also results in the formation of DA o-quinone, which 
readily participates in nucleophilic addition reactions with sufhydryl groups on free cysteine, 
glutathione, or cysteine found in protein including DA transporter (Graham et al., 1978; 
Hastings and Zigmond, 1994; Smythies et al., 1998; Whitehead et al., 2001). In addition, it has 
been reported recently that DA auto-oxidation contributes to MAP-induced neurotoxicity to DA 
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terminals, adding support to the role of DA and oxidative stress in this model (LaVoie and 
Hastings, 1999). Taken together, it is likely that increased generation of DA o-quinone by DA 
auto-oxidation is associated with the neurotoxicity of MAP in the brain.  
Glutathione S-transferase M1 (GSTM1) is a subtype of GSTs that detoxify xenobiotics by 
conjugating glutathione. It has been reported that GSTM1 catalyzes a glutathione conjugate of 
catecholamine o-quinones such as aminochrome (Smythies et al., 1998). GSTM1 has an entire 
gene deletion polymorphism and its enzymatic activity is classified into three grades, i.e., a 
highly active genotype (homozygous non-deletion alleles; NN), a moderately active genotype 
(heterozygous non-deletion alleles; DN), and a null genotype (homozygous deletion alleles; 
DD) (McLellan et al., 1997). Recently, it has been reported that the frequency of D allele of 
GSTM1 gene in the patients with schizophrenia was significantly (p=0.0075) higher than that of 
normal controls, suggesting that GSTM1 gene may be associated with an increased 
susceptibility to schizophrenia (Harada et al., 2001a). Thus, it seems that differences in the 
GSTM1 genotype may contribute to the development of MAP abuse. In order to verify a 
potential role of the GSTM1 gene in the neuropathology by MAP abuse, we analyzed a 
polymorphism of the GSTM1 gene in subjects with diagnosed MAP-related disorders and in 
control groups.  
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Methods 
The research was performed after obtaining approval from the ethics committees of each 
institute of Japanese Genetics Initiative for Drug Abuse (JGIDA), and all subjects provided 
written informed consent for the use of their DNA samples for this research. The subjects were 
157 patients (125 males, age: 37 ± 11 years (mean ± SD), age range: 19-69 years; and 32 
females, age: 28 ± 5 years (mean ± SD), age range: 21-47 years) with MAP dependence and 
psychotic disorder meeting ICD-10-DCR criteria (F15.2 and F15.5) who were outpatients or 
inpatients of psychiatric hospitals of JGIDA, and 200 age-, gender- and geographical 
origin-matched normal controls (157 males, age: 37 ± 11 years (mean ± SD), age range: 19-69 
years; and 43 females, age: 36 ± 10 years (mean ± SD), age range: 21-58 years) mostly 
consisted of medical staffs who had no past history and no family history of drug dependence or 
psychotic disorders. All subjects were Japanese, born and living in restricted arrears of Japan 
including northern Kyusyu, Setouchi, Tyukyou, Toukai and Kantou.  
The polymorphism studied in this project was the deletion of the entire GSTM1 gene. 
Genotyping for this gene was performed by a combination of two types of polymerase chain 
reaction (PCR) amplification as reported previously (Harada et al., 2001a; 2001b). The first type 
of PCR was used for the detection of a non-deletion allele with the appropriate primers: 
(forward: 5’-CTTCACGTGTTATGGAG GTTC-3’, reverse: 
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5’-GCGAGTTATTCTGTGTGTAGC-3’). The other type of PCR was used for the detection of a 
deletion allele with suitable primers: (forward: 5’-ACAGAGGAAGGGTGCATTTGATA-3’, 
reverse: 5’-GACATTCATTCCCAAAGCGACCA-3’); both types of PCR were followed by 
agarose gel electrophoresis with ethidium bromide staining. Allele frequencies were calculated 
by gene counting and the differences between groups were evaluated by Fisher’s exact test. The 
odds ratio (OD) and 95% confidence intervals were calculated to evaluate the effects of the 
different genotypes. 
 
Results 
The GSTM1 genotypes and the allele frequencies in MAP abusers and controls are shown 
in Table 1. The genotype distribution in both abusers and controls was within the 
Hardy-Weinberg equilibrium. We found that a difference in the frequency of deletion (D)/ 
non-deletion (N) alleles between the female abusers and female controls was a trend toward a 
statistical significance (p=0.071). In contrast, there was no significant difference between male 
abusers and male controls (P=0.651). The frequency of carrying the D allele among female 
abusers was significantly higher than that in male abusers (p=0.007, odds ratio: 2.77, 95% CI 
1.30-5.89), whereas no gender difference was shown among control subjects (p=0.297, odds 
ratio: 1.36, 95% CI 0.80-2.31). The genotype distribution difference between female abusers 
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and female controls was significant (p=0.032), whereas no significant difference between male 
abusers and male controls was shown (p=0.819). 
 
Discussion 
Our findings suggest that a deletion of the GSTM1 gene may contribute to MAP abuse 
vulnerability in female, but not in male, subjects. Based on the role played by GSTM1 in the 
antioxidant system preventing neurotoxicity, GSTM1 gene deletion might lead to an excess of 
catecholamine o-quinones (e.g., aminochrome) that are neurotoxic in the brain, including 
dopamine neurons. The reason underlying this gender difference is currently unclear. However, 
recent evidence has been suggestive of gender differences in course of drug dependence and 
drug abuse (Lynch et al., 2002). It has been reported that females enter treatment programs after 
fewer years of amphetamine use, and that females also take less time to become addicted after 
initial use than do males (Westermeyer and Boedicker, 2000). In addition, positive subjective 
effects of d-amphetamine are enhanced during the follicular phase, which correlates with 
changes in estrogen levels (Lynch et al., 2002).  
It has been suggested that gonadal hormones such as estrogen play a role in the 
differences between males and females regarding responses to drugs of abuse (Lynch et al., 
2002). In females, there is an accelerated transition from controlled to uncontrolled use, namely 
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dependence, and that gonadal hormones, particularly estrogen, may play a role in these 
processes (Justice and de Wit, 1999). In studies using rats, estrogen has been revealed to 
enhance the behavioral and neurochemical responses to MAP by increasing stimulated DA 
release (Becker et al., 1999). Furthermore, recent studies using brain imaging technique 
revealed that women have higher levels of DA transporters (Mozley et al., 2001) and lower DA 
D2 receptor affinity in the striatum than men (Pohjalainen et al., 1998), suggesting a lower 
baseline of dopaminergic tone and elevated levels of DA released by MAP in females. Therefore, 
it is likely that gonadal hormones and gender differences in dopaminergic systems may be 
implicated in gender differences related to susceptibility to addiction to psychomotor stimulants. 
Thus, it appears that excess DA released by MAP might generate an excess of DA o-quinone, 
rendering it especially difficult for persons with low-activity GST to detoxify a sufficient 
amount of DA o-quinone. Furthermore, the GSTM1 deletion would influence the susceptibility 
of females to MAP abuse. 
In conclusion, our findings suggest that GSTM1 gene deletion may contribute to a 
vulnerability to MAP abuse in female subjects, but not in male subjects. 
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Table 1  Allele and Genotype Frequencies of the GSTM1 Gene Deletion Polymorphism in MAP Abusers and Controls 
 
                         Male                      Female 
   Abusers (n=125)     Controls (n=157)        Abusers (n=32)   controls (n=43) 
GSTM1 allele frequency 
D                  172 (68.8%)     210 (66.9%)          55 (85.9%)     63 (73.3%) 
N                  78 (31.2%)      104 (33.1%)          9 (14.1%)      23 (26.7%) 
                                P=0.651                           P=0.071 
GSTM1 genotype frequency 
DD                  58 (46.4%)       67 (42.7%)          24 (75.0%)      21 (48.8%) 
DN                 56 (44.8%)       76 (48.4%)           7 (21.9%)     21 (48.8%) 
NN                  11 (8.8%)         14 (8.9%)            1 (3.1%)      1 (2.3%) 
                             P=0.819                           P=0.032* 
Note. D, deletion allele ; N, non-deletion allele. *P<0.05 
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